Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1976 May 28;47(2):135-40.
doi: 10.1007/BF00735811.

Selective neuroendocrine effects of low-dose haloperidol in normal adult men

Clinical Trial

Selective neuroendocrine effects of low-dose haloperidol in normal adult men

R T Rubin et al. Psychopharmacologia. .

Abstract

The neuroendocrine effects of haloperidol, usually reported as side effects of this drug when given in antipsychotic doses, have not been systematically investigated. In the present study five normal adult men were administered saline and two doses of of haloperidol (0.25 mg, 0.5 mg) intramuscularly in a double-blind randomized block design. The anterior pituitary hormones GH, LH, FSH, and PRL were measured in blood samples taken every 20 min for several hours thereafter. The low doses of haloperidol used have been shown by others to alter the human EEG; in our subjects these doses produced no objective or subjective clinical effects. There were no drug related changes in GH, LH, or FSH. PRL, however, showed a prompt, statistically significant, dose-related increase in plasma levels, with a return to baseline with 5 h. Haloperidol has strong dopamine-blocking effects, and the hypothalamic inhibitory mechanism for PRL release is believed to be dopamine-mediated. The results of this study suggest that haloperidol may have utility in low doses primarily for its hypothalamic neuroendocrine effects, and that dose-related PRL release may be a useful paradigm for comparing dopamine-blocking antipsychotic agents in humans.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Am Geriatr Soc. 1975 Jan;23(1):38-41 - PubMed
    1. J Clin Endocrinol Metab. 1975 Jun;40(6):1027-33 - PubMed
    1. J Clin Endocrinol Metab. 1976 Jan;42(1):112-6 - PubMed
    1. Psychopharmacologia. 1975;41(1):27-33 - PubMed
    1. Proc Natl Acad Sci U S A. 1974 Apr;71(4):1113-7 - PubMed

Publication types